Vivaldi Biosciences Inc. Announces Issuance of US Patent for Influenza Vaccines
10/5/2009 11:45:00 AM
NEW YORK--(BUSINESS WIRE)--Vivaldi Biosciences Inc. (Vivaldi), a biotechnology company focused on development of vaccines for influenza, today announced that the United States Patent and Trademark Office has issued US Patent 7,588,768 covering live attenuated influenza vaccines (LAIVs) with modifications to the viral NS1 gene, and methods for producing the vaccines in cell culture systems. This proprietary technology is applicable to rapid development and production of LAIVs against virtually all seasonal and pandemic influenza strains, including novel (swine-origin) H1N1. Vivaldi has exclusive rights to the patented technology and has LAIV candidates in development.
comments powered by